Open position: Temporary QHSE Manager
Invectys, a Franco-American biopharmaceutical company of 25 people, developing innovative immunotherapy products for the treatment of cancers and immune system disorders,…
Read more
Invectys, a Franco-American biopharmaceutical company of 25 people, developing innovative immunotherapy products for the treatment of cancers and immune system disorders,…
FRANÇOIS LESCURE, GENERAL MANAGER OF INVECTYS SAS, TO PARTICIPATE IN THE ABBVIE PARTNERING DAY IN PARIS, FRANCE ON OCTOBER 4TH, 2022 Paris, France, September…
9th International Conference on HLA-G July 4th – 5th 2022 Fondation Singer-Polignac, 43 Avenue Georges Mandel, 75116 Paris Invectys will be…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
The main product of Invectys is a DNA vaccine targeting Telomerase…